| Literature DB >> 25049827 |
K S Lee1, S-H Cha1, H W Kang1, J-Y Song1, K W Lee1, K B Ko1, H T Lee1.
Abstract
Mesenchymal stem cells (MSCs) are often known to have a therapeutic potential in the cell-mediated repair for fatal or incurable diseases. In this study, canine umbilical cord MSCs (cUC-MSCs) were isolated from umbilical cord matrix (n = 3) and subjected to proliferative culture for 5 consecutive passages. The cells at each passage were characterized for multipotent MSC properties such as proliferation kinetics, expression patterns of MSC surface markers and self-renewal associated markers, and chondrogenic differentiation. In results, the proliferation of the cells as determined by the cumulative population doubling level was observed at its peak on passage 3 and stopped after passage 5, whereas cell doubling time dramatically increased after passage 4. Expression of MSC surface markers (CD44, CD54, CD61, CD80, CD90 and Flk-1), molecule (HMGA2) and pluripotent markers (sox2, nanog) associated with self-renewal was negatively correlated with the number of passages. However, MSC surface marker (CD105) and pluripotent marker (Oct3/4) decreased with increasing the number of subpassage. cUC-MSCs at passage 1 to 5 underwent chondrogenesis under specific culture conditions, but percentage of chondrogenic differentiation decreased with increasing the number of subpassage. Collectively, the present study suggested that sequential subpassage could affect multipotent properties of cUC-MSCs and needs to be addressed before clinical applications.Entities:
Keywords: Canine; Differentiation; Mesenchymal Stem Cell; Multipotent; Umbilical Cord Matrix
Year: 2013 PMID: 25049827 PMCID: PMC4093376 DOI: 10.5713/ajas.2012.12488
Source DB: PubMed Journal: Asian-Australas J Anim Sci ISSN: 1011-2367 Impact factor: 2.509
Primer sequences used for RT-PCR analyses in this study
| Markers/gene | Primer sequence (5′-3′) | Amplification size (bp) | Reference |
|---|---|---|---|
| Pluripotency | |||
| OCT3/4 | Forward TGACGACAACAAAAATCT | 128 | Vaags et al. |
| Reverse CAGGCATGTGTTCTCCAG | |||
| NANOG | Forward CCTGCATCCTTGCCAATGTC | 98 | Vaags et al. |
| Reverse TCCGGGCTGTCCTGAGTAAG | |||
| SOX2 | Forward AACCCCAAGATGCACAACTC | 152 | Vaags et al. |
| Reverse CGGGGCCGGTATTTATAATC | |||
| MSC makers | |||
| CD4 | Forward TGCTCCCAGCGGTCACTCCT | 381 | XM534906 |
| Reverse GCCCTTGCAGCAGGCGGATA | |||
| CD8A | Forward GAGGAATGAGCCAGCCGCCC | 303 | NM001002935.2 |
| Reverse GGAGACACCGGCTTGGACGC | |||
| CD25 | Forward GGCAGCTTATCCCACGTGCCAG | 364 | AB501356.1 |
| Reverse ATGGGCGGCGTTTGGCTCTG | |||
| CD33 | Forward TTCGGCACGAGGCCAGGACC | 364 | DR105786.1 |
| Reverse GCTGGCTCCACAACTGGGTGG | |||
| CD34 | Forward GCCTGCTCAGTCTGCTGCCC | 255 | Filioli et al. |
| Reverse TGGTCCCAGGCGTTAGGGTGA | |||
| CD44 | Forward GCCCTGAGCGTGGGCTTTGA | 268 | Filioli et al. |
| Reverse TCTGGCTGTAGCGGGTGCCA | |||
| CD54 | Forward TCCGTGGACCCAGCAGAAGC | 468 | XM542075 |
| Reverse GCGGCACGAGAAGTTGGCGA | |||
| CD61 | Forward GAGGATTGCGCTGCGGCTCC | 412 | NM001003162.1 |
| Reverse AAAGCCGCCCTCTGGGGCAT | |||
| CD80 | Forward GCCTCACCTCTCCTGGTGGGA | 369 | AF257653.1 |
| Reverse TGGCCATACCTGTACAGTGACCTT | |||
| CD105 | Forward GGTTCACTGCATCAACATGG | 278 | XM546483.2 |
| Reverse AAGCTGAAGCGCACATCACC | |||
| CD117 | Forward CTCAGGGGGTGCGAGGGGAA | 332 | AF099030.1 |
| Reverse TGTGTCTGTGCATTAGTCTGGCTG | |||
| Flk-I | Forward CTCCGCACCACATCCGCTGG | 337 | XM539273 |
| Reverse TCCTGCTCGGTTGGCTGGGT | |||
| HMGA2 | Forward AGTCCCTCCAAAGCAGCTCAAAAG | 75 | NM003484.1 |
| Reverse GCCATTTCCTAGGTCTGCCTC | |||
| Housekeeping | |||
| GAPDH | Forward AGTCAAGGCTGAGAACGGGAAACT | 114 | Vieira et al. |
| Reverse TCCACAACATACTCAGCACCAGCA |
Primer sequences used for quantitative PCR analyses in this study
| Markers/Gene | Primer sequence (5′-3′) | Amplification size (bp) | Reference |
|---|---|---|---|
| Chondrocytes | |||
| COL2A | Forward ATCGGGCCTGTCTGCTTCTTGTAA | 134 | Vieira et al. |
| Reverse ACATCAGGTCAGGTCAGCCATTCA | |||
| SOX9 | Forward ACGACTACACTGACCACCAGAACT | 88 | Vieira et al. |
| Reverse ATGTAGGTGAAGGTGGAGTAGAGGCT | |||
| Aggrecan | Forward ACAATGCCCAAGACTACCAGTGGA | 166 | Vieira et al. |
| Reverse TTCTCGTGCCAGATCATCACCACA | |||
| Housekeeping | |||
| GAPDH | Forward AGTCAAGGCTGAGAACGGGAAACT | 114 | Vieira et al. |
| Reverse TCCACAACATACTCAGCACCAGCA |
Figure 1.Morphology (P1–P6) (40X) (A) and cumulative population doubling level (B) and doubling time (C) of cUC-MSC during continuous passages. Data are expressed as the mean±standard error of values obtained by two determinations. * p<0.05.
Figure 2.Expression of pluripotency markers (Oct3/4, Nanog and Sox-2) in cUC-MSC during continuous passages by RT-PCR. GAPDH was used as a control. The cells were positive for all markers.
Figure 3.Expression of MSC surface markers in cUC-MSC during continuous passages by RT- PCR. The results indicated that the cUC-MSCs were positive for CD44, CD54, CD61, CD80, CD90, CD105, Flk-1 and HMGA2, while negative for CD4, CD8A, CD25, CD33, CD34 and CD117.
Figure 4.Differentiation potential of cUC-MSC into mesodermal cell lineage, (A) chondrocyte (Alcian blue). The staining was conducted at 21 d after cells were grown in differentiation media. cUC-MSC showed induction of chondrogenic differentiation. Expression levels of chondrogenic (B) differentiation marker genes were compared between undifferentiated and differentiated cells by Real-time PCR. The expression levels were shown as the mean±standard error of the mean (n = 3). *: p<0.0001 vs undifferented cells.